Actively Recruiting

Age: 18Years +
All Genders
ID05044208

Echocardiographic Predictors of Atrial Fibrillation in Patients With ESUS or TIA Using 7-day ECG Monitoring

Led by Karl Landsteiner University of Health Sciences · Updated on 2023-03-08

200

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

K

Karl Landsteiner University of Health Sciences

Lead Sponsor

N

NÖ Landesgesundheitsagentur, legal entity of University Hospitals in Lower Austria

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the accuracy of echocardiographic measurements to predict atrial fibrillation (AF) in patients who have experienced embolic stroke of undetermined source (ESUS) or transient ischemic attack (TIA). The study focuses on testing the atrial electromechanical conduction time, measured as septal total atrial conduction time (sPA-TDI), and the LaHAsPa-Score, which combines patient data and echocardiographic findings. The goal is to improve risk assessment and monitoring for AF in these patients. Participants undergo a 7-day ambulatory ECG monitoring after routine clinical diagnostics to detect AF. The study follows patients for up to two years to identify AF occurrences, including detection through implantable cardiac monitors or pacemakers if applicable. Other echocardiographic measures and diagnostic tests like 12-lead ECG and Holter monitoring are also compared to the main parameters. During the study, participants receive brain imaging to confirm stroke or TIA diagnosis and echocardiography to measure heart function. They are monitored using ECG devices over extended periods, with regular follow-up visits assessing stroke recurrence, anticoagulation therapy, and cardiovascular events. The primary outcome is detection of previously unrecognized AF during the initial 7-day ECG recording, with secondary outcomes monitored over two years.

CONDITIONS

Brief Title

Echocardiographic Predictors of Atrial Fibrillation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Written informed consent to participate
  • Clinical diagnosis of ischemic stroke or transient ischemic attack (TIA) with brain imaging to exclude hemorrhagic stroke
  • Diagnosis of embolic stroke of undetermined source (ESUS) defined by specific imaging and absence of significant artery narrowing or major cardioembolic sources
  • Patients with TIA meeting the above criteria except ischemic lesions on imaging are optional and symptoms last less than 1 hour
  • Completion of electrocardiogram, transthoracic or transesophageal echocardiography, and at least 24 hours of heart rhythm monitoring
  • Patent foramen ovale allowed
  • Planned or existing implantable cardiac monitor or pacemaker device allowed
Not Eligible

You will not qualify if you...

  • History of atrial fibrillation or atrial fibrillation detected on any prior ECG or heart rhythm monitoring
  • Poor quality echocardiogram preventing measurement of key parameters for the LaHAsPa-Score
  • Wearing time of ECG monitor less than 7 days due to withdrawal, technical issues, or patch problems
  • Life expectancy less than 1 month
  • Patients under legal custody or unable to give written informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 7 days

Participants undergo additional ambulatory ECG monitoring for 7 days to detect atrial fibrillation following routine clinical diagnostics.

1 visit to start monitoring and continuous ECG monitoring for 7 days

Long-term Monitoring

Duration - 24 months

Participants are followed for up to 24 months to monitor for detection of atrial fibrillation or recurrent ischemic stroke using implantable devices or pacemakers if applicable.

Periodic assessments during follow-up visits over 24 months

Trial Site Locations

Total: 1 location

1

University Hospital Tulln

Tulln, Austria, 3430

Actively Recruiting

Loading map...

Research Team

E

Erol Erdik, MD

S

Susanne Holak, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

320-detector Computed Tomography to Assess Myocardial Extrac...

Atrial Fibrillation

Actively Recruiting

1 location

A Preventive, Multidisciplinary Primary Care Intervention Or...

Vascular Disease

Actively Recruiting

1 location

Simple Imaging Versus Standard Imaging Selection in Stroke P...

Stroke, Ischemic

Actively Recruiting

8 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here